Rigel pays $85mn for global rights to first FDA-approved protein degrader in breast cancer

Rigel Pharmaceuticals has agreed to acquire exclusive global rights to Veppanu, the first FDA-approved therapy in a new class of cancer drugs that destroys disease-causing proteins rather than blocking them, paying $85mn upfront to Arvinas and Pfizer in a deal that materially repositions the South San Francisco-based group as a specialist commercial player in protein degradation oncology.

Under the terms announced on Tuesday, Rigel will pay $70mn at signing and a further $15mn upon completion of certain development and manufacturing transition activities. It has also committed to contribute up to $40mn toward development activities over the next four years. Arvinas and Pfizer will be entitled to tiered royalties on commercial sales, ranging from the mid-teens to the mid-twenties percentages, alongside up to $320mn in regulatory and commercial milestone payments. Rigel takes exclusive global rights, including the ability to sublicense outside the United States, with the transaction expected to close in mid-June 2026, subject to antitrust clearance.

Veppanu, known generically as vepdegestrant, is the first Proteolysis Targeting Chimera, or PROTAC, to reach the US market — a class of heterobifunctional molecules engineered to hijack the body's natural protein-disposal machinery and selectively eliminate disease-causing proteins. The mechanism represents a structurally distinct departure from conventional small-molecule inhibitors, which suppress the activity of target proteins without removing them, and is widely viewed in the industry as one of the most consequential new therapeutic modalities of the past decade.

The US Food and Drug Administration approved the drug on 1 May for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed following at least one prior line of endocrine therapy. The National Comprehensive Cancer Network added vepdegestrant as a Category 2A treatment option on 8 May, lending further institutional weight to its clinical positioning. An FDA-authorised diagnostic test is required to confirm ESR1 mutation status before treatment can be initiated.

The commercial rationale rests on the prevalence of acquired resistance in hormone-receptor-positive breast cancer. As many as 50 per cent of patients with ER-positive disease develop ESR1 mutations following exposure to endocrine therapy, conferring resistance to the standard of care and limiting subsequent treatment options. By degrading the mutant receptor entirely rather than competing with it pharmacologically, Veppanu is designed to bypass that resistance mechanism — a clinical proposition supported by data from the global phase 3 VERITAC-2 trial.

The trial, presented at the American Society of Clinical Oncology meeting in 2025 and simultaneously published in the New England Journal of Medicine, showed that vepdegestrant reduced the risk of disease progression or death by 43 per cent compared with fulvestrant, the current standard endocrine therapy in this setting. Median progression-free survival was 5.0 months on vepdegestrant versus 2.1 months on fulvestrant — a statistically significant and clinically meaningful improvement in a heavily pre-treated patient population. Most adverse events were low grade, with musculoskeletal pain, fatigue, nausea and laboratory abnormalities being the most commonly reported.

Erika Hamilton, chief development officer at Sarah Cannon Research Institute and the trial's principal investigator, said vepdegestrant filled "a critical gap in care" for patients with breast cancer carrying ESR1 mutations.

Raul Rodriguez, Rigel's chief executive, said: "We believe it has the potential to become a meaningful driver of long-term growth for Rigel."

For Rigel, the licensing deal represents a substantial strategic transition. The company has historically been a specialist in haematology and immunology, with a portfolio of commercially marketed products targeting thrombocytopenia and other indications. The acquisition of Veppanu is its boldest oncology move to date, extending the platform into solid tumours and into a therapeutic modality — protein degradation — that has attracted some of the largest research and development commitments across the global pharmaceutical industry. Arvinas, the originator of the asset and a publicly listed PROTAC pioneer, retains an economic interest through the royalty and milestone structure, while exiting day-to-day commercial responsibility for the drug.

For Arvinas and Pfizer, the deal monetises a high-profile launch asset while shifting the commercial execution burden to a smaller, more nimble specialist. Pfizer in particular, currently navigating cost pressures and a refocusing of its oncology portfolio in the wake of its Seagen acquisition, has been increasingly willing to license or partner non-core assets rather than build out commercial infrastructure for niche indications. The structure — $85mn upfront, plus contingent development contributions and a royalty stream — is also revealing of the prevailing dynamics in biotech licensing: a relatively modest cash component balanced by significant economic participation in the upside.

The broader implications stretch beyond the immediate parties. Veppanu's regulatory clearance establishes the first market-ready PROTAC product and creates a real-world test of the commercial viability of a class of drugs that academic and industry researchers have been pursuing for nearly two decades. A successful commercial trajectory for vepdegestrant would validate substantial pipeline investments at companies including Arvinas, Foghorn Therapeutics, Kymera Therapeutics, Nurix Therapeutics and several of the larger pharmaceutical groups that have built internal protein degradation platforms.

For investors, the deal also sharpens the focus on Rigel's commercial execution capability. With the asset already FDA-approved, NCCN-listed and supported by a successful pivotal trial, the commercial trajectory turns on diagnostic uptake — the testing requirement that confirms ESR1 mutation status — and on Rigel's ability to build prescriber awareness in a competitive treatment landscape where multiple oral SERDs and other targeted therapies are increasingly available. The economics of the deal, while substantial in absolute terms, are also modest relative to comparable late-stage oncology asset acquisitions in recent years, leaving Rigel with material upside if Veppanu can establish itself as a standard-of-care option in the ESR1-mutated setting.